Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 455, 249-260
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Breast Cancer Research Foundation
- National Cancer Institute (U54CA193489)
This publication has 45 references indexed in Scilit:
- Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancerProceedings of the National Academy of Sciences, 2012
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Clonal evolution in cancerNature, 2012
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance ResearchPLOS ONE, 2011
- Selection of Resistant Bacteria at Very Low Antibiotic ConcentrationsPLOS Pathogens, 2011
- Correlation Between Serum Prostate-specific Antigen and Cancer Volume in Prostate Glands of Different SizesUrology, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Evolutionary Theory of CancerAnnals of the New York Academy of Sciences, 2009
- Adaptive TherapyCancer Research, 2009